Latest News about treatment/resistant depression

Recent news which mentions treatment/resistant depression

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant

August 14, 2024

Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression

July 23, 2024

First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression

April 26, 2024

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

March 28, 2024

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment

February 29, 2024

UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center

November 15, 2023

Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation

October 03, 2023

Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression

September 06, 2023

GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026

August 24, 2023

Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'

July 18, 2023

COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital

July 05, 2023

Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD

May 30, 2023

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer

May 11, 2023

Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression

May 04, 2023

Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results

January 12, 2023

Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far

December 12, 2022

Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments

December 09, 2022

Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes

November 16, 2022

Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders

November 02, 2022

atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing

October 05, 2022

Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound

July 28, 2022

Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows

April 12, 2022

COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction

December 01, 2021

Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying

November 16, 2021

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.